Low CCL21 expression still indicated shorter OS in patients with clear cell renal cell carcinoma (P = 0.017) and patients treated with sorafenib (P = 0.009) (Figure 1B, 1C, 1D, 1E). This evidence concerns the gene CCL21 and clear cell renal carcinoma.